{ POCT Analyzer }

  • Poclight IgE Assay Accurate Insights into Allergic Diseases

     

    1.  What is IgE?

     

    In our blood, there exists a special class of protein known as immunoglobulin, which is an important component of the immune system. Among them, IgE (immunoglobulin E), despite its extremely low concentration, accounting for only 0.002% of the total immunoglobulin, it acts as a key "messenger" in triggering allergic reactions. This antibody produced by B lymphocytes primarily protects the human body in two ways: one is to resist parasitic infections, and the other is to trigger an immune response when encountering allergens.

     

    When allergens (such as pollen, dust mites or certain foods) enter the human body, the immune system recognizes them as "foreign invaders" and prompts B cells to produce IgE antibodies against the allergen. These IgE will specifically bind to the surface of mast cells and basophils, causing the body to enter a "sensitized state". When exposed to the same allergen again, IgE immediately activates the "alarm system", prompting cells to release inflammatory mediators such as histamine, triggering allergic symptoms like sneezing, itchy skin, and breathing difficulties - this is the fundamental principle of what we commonly refer to as an allergic reaction.

     

    2.  IgE Testing: Purpose and Applications

     

    IgE detection has become a critical tool in the diagnosis of allergic diseases.

     

    IgE Assay Application

     

    Clinical significance: Studies show that approximately 30% of patients with allergic diseases exhibit significantly elevated levels of total serum IgE. Moreover, specific IgE testing demonstrates over 85% accuracy in identifying the types of allergens involved. This test is mainly applicable to three types of people:

    ✓ Patients with recurrent skin itching, urticaria, allergic rhinitis and other symptoms.

    ✓ Individuals with a history of asthma and unknown cause.

    ✓ High-risk groups with a family history of allergic diseases.

     

    Note: IgE test results must be interpreted in conjunction with clinical symptoms. For instance, in patients with hay fever, allergen-specific IgE levels may rise 2-4 weeks before the pollen season begins. In cases of food allergy, relevant IgE antibodies can trigger an immune response within 1-2 hours after ingestion of the allergenic food. Through dynamic monitoring of IgE levels, physicians can not only confirm a diagnosis but also develop personalized desensitization treatment plans, which have been shown to reduce the risk of acute asthma attacks by 40%-60%.

     

    3.  From Testing to Management: Comprehensive Prevention and Control of Allergic Diseases

     

    IgE testing is only the first step in the management of allergic diseases. Clinical practice has shown that personalized prevention and control plans, developed based on test results, can improve patients' quality of life scores by 35%~50%. For patients allergic to dust mites, in addition to the use of antihistamines, regular environmental control measures, such as using mite-proof bedding and air purifiers, can reduce the frequency of symptom episodes by 40%. Patients with food allergies, on the other hand, need to strictly avoid allergenic foods and carry an epinephrine auto-injector at all times in case of accidental exposure.

     

    IgE Test Kit

     

    With advances in precision medicine, IgE testing technology is also continuously evolving. The new generation of testing methods can not only quantitatively analyze antibody levels but also predict the severity of allergic reactions by detecting IgE subtypes.

     

    In an era of ongoing iteration in in vitro diagnostic technologies, Poclight IgE test kit, with its innovative technology, exceptional performance, user-friendly operation, and reliable quality, offers a new option for the precise diagnosis of allergic diseases. In the future, by integrating genetic testing and artificial intelligence algorithms, we hope to achieve early warning and precise intervention for allergic diseases, helping more people break free from the burden of allergies.

     

    Advantages of Poclight IgE Test Kit: Innovative CRET Technology Enables Precision "Signal-Switch" Detection

     

    C5000 POCT Analyzer

     

    Technology Principle:

    ✓ Utilizes a homogeneous chemiluminescence approach.

    ✓ Integrates antigen-antibody reactions with chemiluminescent signals.

     

    Workflow:

    ● The target substance binds with an acridinium ester-labeled DNA antibody to form an immunocomplex.

    ● Graphene oxide quenches the remaining unbound acridinium ester-labeled DNA fragments.

    ● This homogeneous process eliminates the need for separation and washing steps.

    ● A chemiluminescent reaction is initiated by adding an excitation solution.

     

    Performance Specifications:

    ✓ High Sensitivity: Detection sensitivity of 0.1 IU/mL.

    ✓ Wide Linear Range: 0.1–2500 IU/mL, fully meeting clinical testing requirements.

    ✓ Excellent Precision: Intra-assay CV ≤10% and inter-assay CV ≤15%, ensuring stable and reliable results.

    ✓ Rapid detection: in just 5 minutes, minimal sample volume of 50 µL, simple operation, low cost, high-quality CLIA methodology, innovative CRET patented technology, precise results, and a wide linear detection range.

    ✓ Ease of Use: Minimal training required

     

    Key Advantage (vs. Traditional ELISA):

     

    ●  Exceptional Speed: Reduces the detection time from 3 hours to just 5 minutes.

    ●  Operational Simplicity: The homogeneous assay format removes the need for cumbersome washing and separation steps.

    Compatible with Poclight C5000 POC CLIA Analyzer

     

     

    Operation

     

    To learn more about cooperation regarding Poclight's 5-generation CLIA solutions, please contact us.

     

  • World Stroke Day Poclight CRET for Hidden Stroke Detection

     
    1.  The Invisible Warning: Activated Platelets

     

    October 29 marks World Stroke Day, a reminder to pay attention to brain health and take action to prevent strokes, one of the leading causes of death and disability worldwide.

    Strokes can occur suddenly, and certain physiological changes may precede clinical symptoms. Early detection is therefore essential for timely risk assessment and intervention.

     

    Many people associate stroke with high blood pressure, high cholesterol, and atherosclerosis. While these are important risk factors, there’s a crucial, often overlooked element — abnormal platelet activation.

    Normal platelets help stop bleeding, but when excessively activated, they become overly sticky and prone to clumping. Like tiny “time bombs,” they can form blood clots that block cerebral blood vessels, leading to ischemic stroke.

    Traditional blood tests may not fully reflect platelet activation; direct monitoring of platelet functional state provides more comprehensive information.

     

    2.  The Gold Standard: Platelet Activation Markers

     

    Early detection of platelet activation is key to predicting thrombotic events. Important markers include:

     

    Platelet Activation Markers

     

    ● CD62P (P-Selectin): Recognized as the gold standard for platelet activation. Its surface expression signals the initiation of clot formation.

    ● PAC-1: A widely accepted marker for early platelet activation.

    ● CD42a, CD42b, CD41, CD61: Maintain platelet structure and function, mediating aggregation, adhesion, and secretion.

    These markers allow clinicians to precisely assess platelet activation and intervene before stroke occurs.

     

    Testing Significance

     

    1)  Personalized Antiplatelet Therapy

    Provides precise guidance for the use of antiplatelet drugs such as aspirin and clopidogrel, enabling individualized treatment.

    2)  Stroke Risk Assessment

    Detects hidden hypercoagulable states in time, offering early warning for cardiovascular and cerebrovascular events.

    3)  Medication Guidance & Efficacy Monitoring

    Evaluates whether antiplatelet therapy is effective and identifies potential “drug resistance,” allowing timely adjustment of treatment plans.

     

    3.  CRET Platelet Activation Measurement

     

    Poclight Platelet Activation Function Analyzer: Real-Time, Dynamic, and Precise

    Poclight CRET Analyzer and reagents offers a powerful tool for platelet monitoring, helping clinicians make informed decisions regarding transfusion strategies, bleeding/thrombosis risk prediction, and treatment optimization.

     

    Poclight Platelet Activation Features

     

    With CRET Measurement, clinicians can detect the “invisible” culprits of stroke early, enabling timely intervention and improved patient outcomes.

     

    For detailed information and partnership options, please contact us.

     

  • Expand Your Diagnostic Portfolio - Rapid Tumor Marker Testing with Poclight CLIA Solutions

    1.  Global Cancer Burden: Facts & Figures

    The Rising Global Cancer Burden

    According to the latest report from the World Health Organization (WHO) and its cancer agency, IARC, there were approximately 20 million new cancer cases and 9.7 million deaths worldwide in 2022, with around 53.5 million people alive within five years of a cancer diagnosis.

     

    Global Cancer Incidence

     

    Lung, breast, and colorectal cancers were the three most common types, with lung cancer remaining the leading cause of death. Low-income countries face higher mortality due to late diagnosis and inadequate care.

     

    By 2050, global new cancer cases are projected to reach 35 million, with the largest increases in low- and middle-HDI countries. WHO calls for strengthened cancer care coverage and investment to ensure accessible, high-quality cancer diagnosis and treatment for all.

     

    The Importance of Early Screening

    ● Up to 40% of cancer-related deaths could be prevented through early detection and timely intervention. (The Lancet Global Health)

    ● Developed countries show higher screening coverage, while accessibility remains a challenge in developing regions.

    ● The trend toward multi-cancer early detection (MCED) is accelerating globally, promoting a more comprehensive approach.

     

    For Breast Cancer Awareness Month (October)

    ● Breast cancer is the most common cancer among women worldwide.

    ● Self-examination is recommended starting at age 20.

    ● Women over 40 are advised to undergo imaging combined with biomarker screening every 1–2 years.

    ● Early detection (Stage I) can lead to a 5-year survival rate exceeding 90%.

    Recommendations and statistics are based on sources, including WHO guidelines, the American Cancer Society (ACS), EUSOMA guidelines, and global cancer data from GLOBOCAN/IARC and the NCI SEER database.

     

    2.  Key Tumor Markers and Their Clinical Significance

     

    Biomarker

    Associated Cancer Type(s)

    Clinical Use

    PSA

    Total Prostate-specific antigen (tPSA)Test Kit

    Prostate Cancer

    Routine screening marker; early detection and therapy monitoring

    CEA

    Multiple Cancers (colorectal, lung, breast, etc.)

    Broad-spectrum marker for diagnosis aid and recurrence monitoring

    AFP

    Liver Cancer

    Key indicator for hepatocellular carcinoma screening and differentiation

    CYFRA21-1

    Lung Cancer (especially squamous type)

    Supports diagnosis and treatment evaluation

    CA19-9

    Pancreatic & Gastrointestinal Cancers

    Digestive system malignancies and therapy monitoring

    CA125

    Ovarian Cancer

    Screening and disease progression evaluation in female patients

     

    Combining markers increases sensitivity and specificity by compensating for individual testing limitations:

    ● Ovarian cancer: CA125 + HE4 achieves 93.8% accuracy.

    ● Pancreatic cancer: CA19-9 + CEA + CA125 raises sensitivity to 82%.

    ● Prostate cancer: f/t PSA ratio reduces false positives by 30% in the gray zone.

     

    Application Department

     

    3.  Poclight’s Innovative Diagnostic Solutions

     

    In today’s evolving healthcare landscape, laboratories and diagnostic providers are seeking faster, more reliable, and accessible cancer testing solutions, yet traditional immunoassay systems often require high costs, long turnaround times, and complex operation.

    Poclight offers a comprehensive portfolio that empowers both distributors and laboratories to expand access to high-quality cancer diagnostics anywhere, anytime.

     

    1) Advanced Platform: C5000 Dry Chemiluminescence Immunoassay Analyzer (Dry CLIA Analyzer)

    C5000 CLIA Analyzer

     

    2) Featured Tumor Marker Panel

    ✓ Combined tumor marker testing: PSA, CEA, AFP, CYFRA21-1, CA19-9, CA125

    ✓ Covers multiple major cancer types (liver, lung, prostate, gastrointestinal, ovarian)

    ✓ Fast, accurate, and suitable for hospitals, health centers, and primary care facilities

     

    Poclight Tumor Markers Specifications

     

    ✓ Rapid detection in just 5 minutes, minimal sample volume of 50 µL, simple operation, low cost, high-quality CLIA methodology, innovative CRET patented technology, precise results, and a wide linear detection range.

     

    Ease of Use: Minimal training required

    Operation

     

    More tumor marker and other assays in progress

     

    Poclight Biotech is actively seeking global partners who share our vision for accessible, high-quality diagnostics.

    Reach out to us to explore collaboration opportunities or to learn how our solution can fit into your portfolio.